Nimotuzumab in Adults With Glioblastoma Multiforma
Determination of efficiency of nimotuzumab in adults with glioblastoma multiforma
Adults With Glioblastoma Multiforma
DRUG: nimotuzumab
Progression-free interval determined by MRI, week 12, 24, 36, 52
Overall survival Time to reintervention Response rate according to RECIST criteria Toxicity according to CTC criteria Symptom control Quality of life, week 12, 24, 36, 52
The objective of the present study is a comparison of treatment of patients with newly diagnosed glioblastoma multiforme grade IV. Patients will be randomized in one of two arms when included. Patients randomly assigned to arm A will receive Nimotuzumab (OSAG 101) plus Temozolomide concomitant with standard radiotherapy. Patients randomised in arm B will receive standard radiotherapy plus Temozolomide treatment.